Category: News

(St. Louis, Missouri, July 31, 2013) Gallus Biopharmaceuticals, LLC (Gallus) has signed a development and manufacturing supply agreement with Genzyme, a Sanofi Company the pioneer in the development and delivery of transformative therapies for patients with rare and special unmet medical needs for over 30 years. As part of the multi-year agreement Gallus will provide process and method development, scale-up, clinical supply and preparation for commercial […]

July 2013 issue of Life Science Leader magazine – Written by Rob Wright This year there have been a number of companies announcing pharmaceutical manufacturing plant closures. For example, Catalent Pharma Solutions announced the closing of its Allendale, NJ, facility. Solgar Inc., a subsidiary of NBTY, announced the closing of its plant in Lyndhurst, NJ. These pharma manufacturing plant closings equate to 196 jobs lost for New […]

(St. Louis, Missouri – April 22, 2013) – Gallus BioPharmaceuticals, LLC (Gallus) today announced performance details of its Factory of the Future today. Gallus built an 8,000 sq ft open-ballroom suite using Xcellerex 2,000 L disposable bioreactors and has been operating it for the last year. To date, four mammalian cell lines have been used in multiple bioreactor runs, demonstrating robust scale-up performance, and clinical materials […]

Life Science executive with an extensive global network adds to already deep leadership team. (St. Louis, Missouri February 26, 2013) — Gallus BioPharmaceuticals, LLC (Gallus) announced today the appointment of Mr. Shailesh Maingi to its Board of Directors as an independent director. Gallus is pleased to announce the addition of Shailesh Maingi to its Board of Directors. Shailesh, a life sciences executive with an extensive global […]

Leverage knowledge to promote and expand continuous processing in the biotech industry Pine Brook, NJ and St. Louis, MO, USA: January 22, 2013 –Refine Technology, LLC (Refine), the developer and worldwide supplier to the biotech industry of the ATF™ System, a best-in-class cell retention device, and Gallus BioPharmaceuticals, LLC (Gallus), the industry leading contract bulk biopharmaceuticals manufacturer, today announced a collaboration to optimize continuous cell […]

St. Louis (Dec. 6, 2011) – Gallus BioPharmaceuticals (Gallus) was recognized at the Greater St. Louis Top 50 awards ceremony on November 15th 2011 for its establishment as a new contract manufacturing business, its regional contributions, and its positive impact to the business community. The recognition involved the successful acquisition of the FDA-approved, commercially-certified biologics manufacturing plant and 160 of its employees from Centocor Biologics, LLC […]

Gallus Acquiring FlexFactory® Bioproduction Lines and Single-Use Bioreactors; Xcellerex Partners to Help Customers Gain Access to Commercial Biomanufacturing Facility Marlborough, MA, and St. Louis, MO May 24, 2011 – Xcellerex, Inc. and Gallus BioPharmaceuticals, LLC today announced that they have entered into a collaboration that quickly provides Gallus with expanded cGMP biomanufacturing capacity by leveraging the key advantages of the turnkey Xcellerex FlexFactory® GMP manufacturing platform […]